SCHEMBL1049129

SCHEMBL1049129

COc1ncc(-c2cc3cc[nH]c(=O)c3c(Nc3ccc4cn[nH]c4c3)n2)cn1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ZAP70 P43403 12/20 0.48
RET P07949 2/20 0.44
KDR P35968 2/20 0.44
SYK P43405 5/20 0.44
RAF1 P04049 1/20 0.41
BRAF P15056 1/20 0.41
EIF2AK2 P19525 1/20 0.40
PLK4 O00444 1/20 0.40
CHEK1 O14757 1/20 0.40
PDPK1 O15530 1/20 0.40
DYRK3 O43781 1/20 0.40
JAK2 O60674 1/20 0.40
ROCK2 O75116 1/20 0.40
PRKD3 O94806 1/20 0.40
MAP4K4 O95819 1/20 0.40
ABL1 P00519 1/20 0.40
NTRK1 P04629 1/20 0.40
INSR P06213 1/20 0.40
FYN P06241 1/20 0.40
CDK1 P06493 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1047287 0.93 ZAP70 (0.48) ZAP70RETKDRSYKROCK2
SCHEMBL1049511 0.85 ZAP70 (0.61) ZAP70RETKDRSYKEIF2AK2
SCHEMBL1045442 0.85 ZAP70 (0.46) ZAP70RETKDRSYKRAF1
SCHEMBL1045652 0.85 ZAP70 (0.45) ZAP70RETKDRSYKEIF2AK2
SCHEMBL1048646 0.85 ZAP70 (0.46) ZAP70RETSYKMAPK1
SCHEMBL1048662 0.83 ZAP70 (0.44) ZAP70RETKDRSYKEIF2AK2
SCHEMBL1044891 0.83 ZAP70 (0.48) ZAP70RETKDRSYKEIF2AK2
SCHEMBL1045634 0.83 ZAP70 (0.62) ZAP70RETKDRSYKEIF2AK2
SCHEMBL1045508 0.81 ZAP70 (0.54) ZAP70RETKDRSYKEIF2AK2
SCHEMBL1045728 0.81 ZAP70 (0.46) ZAP70RETSYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8546370-B2 Compounds and compositions as kinase inhibitors IRM LLC (BM) 2013-10-01 US claimed
US-20110003798-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2011-01-06 US claimed
EP-2238137-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2010-10-13 EP claimed
WO-2009097287-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2009-08-06 WO claimed
US-8546370-B2 Compounds and compositions as kinase inhibitors IRM LLC (BM) 2013-10-01 US disclosed
CN-101990539-A Compounds and compositions as kinase inhibitors IRM LLC 2011-03-23 CN disclosed
US-20110003798-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2011-01-06 US disclosed
EP-2238137-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2010-10-13 EP disclosed
WO-2009097287-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2009-08-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003798-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FYN, SYK, RET ZAP70 4/4885RET 3/4885KDR 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.